Compare Ross Stores, Inc. (ROST) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Revvity Inc — how do they compare? Ross Stores, Inc. trades at $222.41 (market cap $71.94B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Ross Stores, Inc. is far larger — about 4.2× Revvity Inc's market cap, and Ross Stores, Inc. pays the higher dividend (0.79%). Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Revvity Inc for 12 Days on average.
| ROST | RVTY | |
|---|---|---|
Market Cap | $71.94B | $16.98B |
Volume | 2,002,519 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $157.36 |
52-Week Low | $147.71 | $82.26 |
Typical Hold Time | 48 Days | 12 Days |
Enterprise Value | $72.39B | $19.30B |
Dividend Yield | 0.79% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $225.20, down 0.15% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters, posting robust profitability with 42.63% ROE and 10.85% net margin. Revenue growth continues with 2025 revenue reaching $21.13B, while analyst consensus remains bullish with a $274.14 price target representing 22% upside potential.
ROST presents a compelling investment case with strong earnings momentum and expanding margins, though technical indicators suggest near-term pressure. Key risks include competitive pressures in discount retail and potential margin compression from rising costs. The stock's current valuation at 27.23 P/E appears reasonable given growth prospects, supported by institutional confidence and strategic store expansion initiatives.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
